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ABSTRACT 
 
 
ABSTRACT 
 
OBJECTIVES:  
It is well established that tadalafil inhibits phosphodiesterase‑5 (PDE-
5) leading to increased cellular levels of cGMP. Tadalafil has been shown to 
relax various isolated smooth muscles. However, its effect on human 
myometrium has not been determined. Hence, the study was conducted to 
determine whether tadalafil inhibits the potassium chloride (KCl)-induced 
contractility of isolated non-pregnant human myometrium, and if so, to study 
the probable mechanism of action involved. 
METHODS:  
Myometrial tissue was obtained from 11 patients who underwent 
hysterectomy. The effect of tadalafil on 55 mM KCl‑induced contractility of 
isolated non-pregnant human myometrium was studied using a physiograph. 
The ability of the specific calcium‑sensitive potassium (BKCa) channel 
blocker iberiotoxin (100 nM) to reverse the inhibitory effect of 40 μM 
tadalafil on KCl‑induced myometrial contractility was also studied. The 
percent inhibition caused by tadalafil with and without iberiotoxin was 
calculated and statistically analyzed using the Wilcoxon signed-rank test in 
‘R’ program (3.1.1). 
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RESULTS:  
Tadalafil produced a statistically significant inhibition of 
KCl‑induced myometrial contractility. The inhibition of 40 μM tadalafil on 
myometrial contractility was totally and significantly reversed by the 
concurrent administration of iberiotoxin. 
CONCLUSIONS:  
These results suggest that tadalafil inhibits the contractility of isolated 
non-pregnant human myometrium. The results also suggest that tadalafil does 
so by opening BKCa channels. Hence tadalafil could possibly be evaluated 
for use as a uterine relaxant for the management of clinical conditions like 
preterm labour that require myometrial relaxation. 
Key words: Contractility, myometrium, tadalafil, non‑pregnant, iberiotoxin.
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INTRODUCTION 
 
 
 
INTRODUCTION 
The uterus, the cavern where each and every human being is 
originated is a mysterious organ. It varies in structure and function 
considerably according to the immediate physiological needs of a female 
body. It follows a pristine physiological rhythm which governs the fertility of 
the reproductive woman and the survival and the parturition of the fetus. The 
complex anatomy of the uterus at various levels contributes to the above 
processes in harmony. 
The variety of disorders of the uterus is a unique feature by itself. 
There are certain disorders that mainly deal with increased contractility of the 
uterus and certain disorders that deals with decreased contractility of the 
uterus. In case of decreased contractility, like prolonged labor, there is need 
for augmentation or induction of the labor in some cases (1). But when there 
is increased contractility, e.g. dysmenorrhea or preterm labor, we need to 
relax the uterine smooth muscle by giving certain drugs. Primary 
dysmenorrhea is caused by excessive uterine muscle contractions. The 
treatment for dysmenorrhea commonly includes nonsteroidal anti-
inflammatory drugs, oral contraceptive pills and GnRH analogs (2,3).  
Tocolytics like glyceryl trinitrate (4), nifedipine (5) and magnesium (6) have 
also been tried with reassuring success for dysmenorrhea. Herbal and dietary 
therapy has also been tried in the ancient societies for the same (7). 
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The problem of preterm labor is intractable with rate of prevalence 
around 5-15 % in different countries including India depending on 
demographic and geographical features (8). Among the multiple causes of 
preterm delivery preterm labor is the leading cause (8). Cerebral palsy, lung 
disease, deafness as well as neonatal death can be the sequelae of preterm 
delivery. In developing countries the neonatal mortality rate is high as the 
care for these babies is expensive, often beyond the reach of the poor 
population. Even though the survival of preterm babies has improved 
tremendously, the cost of care, survival rate (as compared to full term) and 
preterm related complications have not improved much. Tocolytics causing 
relaxation of myometrium, are commonly used group of drugs to stop the 
progression of preterm labor. Even though there are multiple groups of drugs 
available for treatment of preterm labor, it is a dilemma to select the first line 
drug due to lack of specificity, presence of side-effects, and weak evidence 
for support of the use (9). Drugs used as tocolytics in preterm labor include 
β-sympathomimetic, calcium channel blocking agents, oxytocin receptor 
antagonist, prostaglandin synthetase inhibitors, and magnesium sulphate. All 
these drugs have their own advantages and disadvantages. β-
sympathomimetic (ritodrine, terbutaline) can cause arrhythmia, pulmonary 
edema,vasculitis – as a gross their efficacy is lower than calcium channel 
blockers and oxytocin receptor antagonist, so they are not recommended as a 
tocolytic agent.  
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Because of less side effects and superior efficacy, calcium channel 
blocking agents (nifedipine) are preferred as of now. Oxytocin receptor 
antagonist (atosiban) though having better side effect profile compared to 
calcium channel blockers, is less efficacious and costlier (10). Prostaglandin 
synthetase inhibitors (indomethacin) have the potential to cause fetal risks. 
Magnesium sulphate is also not preferred as a tocolytics due to less efficacy 
and increased mortality of newborn (11). 
Main purpose of tocolysis is to delay delivery at least by 48 hours, to 
allow maximum effect of antenatal glucocorticoids which is given for 
maturation of the fetal lung as well as transportation of the mother to a 
specialized center where neonatal care is available. There is no clear 
guideline or a drug of choice for the treatment of preterm labor (12). 
Tadalafil inhibits cGMP-specific phosphodiesterase type 5, leading to 
increasing levels of cGMP, causing venodilation and therefore cause erection 
of the penis. It is also used to treat pulmonary artery hypertension since it 
relaxes the smooth muscle cells in the pulmonary arterial wall (13). Contrary 
to popular belief, tadalafil is also safe to be used in patients with previous 
myocardial infarction (MI) or in risk of developing MI (14) except for the 
absolute contraindication of taking it along with a nitrate (15). 
Tadalafil has been tried out for various other conditions. It has been 
shown to be effective in lower urinary tract infection in benign prostatic 
hyperplasia patients (16). Another congener (Sildenafil) of the same group 
has been shown to relax human non-pregnant myometrium (17) and pregnant 
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myometrium (18).This action has interestingly been found to be independent 
of the already known phosphodiesterase inhibitory activity and is probably 
related to activation of large conductance potassium channels (18). This has 
shown to be true in other smooth muscle tissues also (19). 
The expression of receptors including BKCa receptor on a pregnant 
human myometrium varies widely from that of the non-pregnant human 
myometrium (20). The action of tadalafil or its mechanism of action on non-
pregnant myometrium is not determined till date. 
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AIMS AND OBJECTIVES 
 
 
AIMS AND OBJECTIVES 
 
Hypothesis: 
• Tadalafil can cause relaxation of isolated non-pregnant human 
myometrium in-vitro. 
Aim: 
• To determine whether tadalafil, a phosphodiesterase inhibitor, 
inhibits the contractility of isolated non-pregnant human 
myometrium. 
Objective: 
1. To study the effect of tadalafil on the height and area under 
the contractile curve of potassium chloride induced 
contraction of human non-pregnant myometrium. 
2. If any relaxant effect of tadalafil is found - study the probable 
mechanism of action using suitable reversal agents. 
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REVIEW OF LITERATURE 
REVIEW OF LITERATURE 
Anatomy of Uterus 
In the female reproductive system one of the vital organs is the uterus. 
It is a hollow and thick walled muscular structure. The body of the uterus 
extends from the fundus in the upper end to the cervix in the lower end. The 
uterine wall is made up of three main layers. From inside outward these 
layers are the endometrium, myometrium, and perimetrium. Amongst these 
three layers myometrium is the largest component. 
The myometrium is composed of a fibromuscular layer. Smooth 
muscles are present in this fibromuscular layer.  In this fibromuscular 
meshwork blood vessels, lymphatic vessels and nerves are distributed. This 
muscle layer is often subdivided into four more layers, from inside outward 
those are: longitudinal muscle layer, oblique muscle layer, circular muscle 
layer, vascular layer along with longitudinal muscles. Beyond this outer 
vascular layer with longitudinal muscles there is the perimetrium. 
Figure 1. Anatomy of Uterus 
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Microstructure of the Body of Uterus 
The body of the uterus comprises three layers. These are (from lumen 
outwards): endometrium (the mucosa), myometrium (the muscular layer) and 
serosa (the adventitia, part of the visceral peritoneum) 
Endometrium 
It is the highly vascularized mucosal layer of the uterus, velvety in 
appearance. It is formed by a single layered simple columnar epithelium 
supported by the endometrial stroma and a layer of connective tissue. The 
innermost columnar cell layer is ciliated and secretory and lines the lumen of 
the uterus. The underlying stroma is a thick layer of lamina propria (areolar 
connective tissue). Endometrial glands invaginate from the columnar 
epithelium to the myometrial layer. The endometrium is functionally divided 
into two layers— stratum functionalis, which lines the lumen and sloughs off 
periodically with menstruation and stratum basalis, which regenerates the 
stratum functionalis before the next menstruation. The arcuate arteries 
arranged circularly in the myometrium branch and penetrate deep as radial 
arteries and divide into two kinds of arterioles— straight arterioles which 
supply the stratum basalis and spiral arterioles which supply the stratum 
functionalis. Spiral arterioles change significantly with the menstrual cycle. 
The extensive vasculature of this layer helps in the implantation of the 
embryo and development of the placenta. 
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Myometrium 
The exact orientation of the myometrial fibers remain controversial (21), yet 
traditionally it is believed to consist of four muscular layers (22): 
a) Submucosal layer (innermost) — mainly longitudinal and 
some oblique fibers, except at the os where it forms a circular 
ring 
b) Vascular layer— thick layer with longitudinal fibers and 
vessels 
c) Supravascular layer— thick layer with predominantly circular 
fibers 
d) Subserosal layer— outer, thin layer with longitudinal fibers 
The muscular fibers of the outer two layers of the uterus converge at 
the isthmus of the fallopian tube and continue in it with some fibers reaching 
the uterine ligaments. The muscle fibers merge with the connective tissue 
containing collagen and elastin at the junction of the body of uterus and 
cervix. 
The submucosal fibers of the lateral wall of the uterine lumen which 
run from the fundus to the cervix are structurally different from the rest of the 
myometrial fibers and may be involved in the coordination of the contraction 
of the uterus (22). Microscopically, muscle fibers are derived from multiple 
fasciculi which consist of numerous myocytes and connective tissue. Further, 
myocytes are arranged into bundles, which are again of multiple types 
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including connecting bridges formed by dense bundle of myocytes. The 
bundles merge, dichotomize and intertwine with each other (23). There is 
sufficient amount of interlacing of the uterine fibers and vast amount of 
heterogeneity of fibers in any given part of myometrium (along with the 
presence of oblique fibers) and there is no significant difference in 
contractility of uterine strips in-vitro when measured from transverse strips 
and longitudinal strips of uterus (24). 
Serosa 
It is composed of visceral peritoneum. There are no smooth muscle 
fibers in the serosa. The effect of serosa on the contractility of myometrium 
has not been studied before. 
 
Figure 2. Layers of uterus 
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Vascular supply to the Uterus 
Uterine arteries supply the uterus. It is a branch of the anterior 
division of the internal iliac artery. It reaches the uterus at the level of the 
cervico-uterine junction. It branches into multiple small arteries 
anastomosing with the ovarian artery superiorly and the vaginal artery 
inferiorly. The uterine artery undergoes marked hypertrophy during 
pregnancy. The multiple branches of the uterine artery enter the uterine wall, 
divide and run circumferentially as the anterior and posterior arcuate arteries. 
They are ramified and thinned out as they approach the anterior midline and 
the posterior midline, which makes the uterus less vascular in the midline. 
Helical arterioles are the tortuous terminal branches of the uterine artery. 
They continue as dense capillary plexuses in the endometrial and the 
myometrial layer (22). 
 
Figure 3.Vascular supply of uterine layers 
19 
 
The uterine veins run adjacent to the arteries and drain into the 
internal iliac veins. The lymphatic drainage of the uterus is into three groups 
of lymph nodes: the external iliac, internal iliac and the obturator group of 
lymph nodes. There is some amount of drainage into the para-aortic and 
inguinal group of lymph nodes also. 
 
Innervation 
The inferior hypogastric plexus innervates the uterus. The nerves 
usually accompany the vessels and end in the endometrium. Efferent 
pregangionic sympathetic fibers are derived from T12 to L1 spinal segments 
and preganglionic parasympathetic from the S2 to S4 spinal segments. 
Sympathetic stimulation causes contraction of the uterus and vasoconstriction 
while parasympathetic stimulation causes the reverse (22). 
 
Physiology of the Uterus 
The knowledge of the functioning of the normal human myometrium 
in various physiological states is very important for understanding the 
cellular mechanism of the drug under study. The uterus is a hollow muscular 
organ: the smooth muscles present here are capable of contracting by 
themselves. Upper uterine segment contraction is different from that of the 
lower uterine segment in the presence of prostaglandins pointing towards the 
heterogeneity of receptors and signaling mechanisms in different anatomical 
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parts of the uterus (25). Different types of modulators of contraction and 
excitation-contraction coupling have been studied at cellular and molecular 
levels in the recent past (26). The endometrium is made up of a number of 
different cell types and is an active, secretory structure in nature which 
releases a number of substances that can affect the activity of the smooth 
muscle layer. These substances include prostanoids, endothelin and platelet 
activating factor (27). 
 
Mechanism of smooth muscle contraction 
Smooth muscle cells are small cells with about 80-90% of the cell 
filled with myofilaments. Smooth muscle is composed of actin and myosin 
filament like skeletal muscle but it does not have troponin complex that is 
required for skeletal muscle contraction. Generally skeletal muscle have more 
myosin than actin, which is the opposite in smooth muscle in which there are 
two to ten times more actin than myosin (28). In myometrium actin is present 
six times more than myosin (29). So in case of smooth muscle contraction the 
mechanism is different compared to skeletal muscle. One of the major factors 
that play a role in smooth muscle contraction is change in calcium ion 
concentration inside the cell. Adenosine triphosphate (ATP) is broken down 
to adenosine diphosphate (ADP) to yield energy for contraction. Only one 
molecule of ATP is required for each cycle of contraction. Smooth muscle 
contraction is prolonged and tonic contraction. 
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Smooth muscle contains a large amount of the regulatory protein 
calmodulin. This is different in contrast to skeletal muscle contraction where 
troponin is required. Calmodulin activates the myosin cross-bridges. 
Activation and subsequent contraction occurs by the following steps: 
• Calcium and calmodulin join together and form a complex. 
• This calcium-calmodulin complex joins with myosin kinase 
and activates it (this causes phosphorylation). 
• There is one regulatory chain in the myosin head. This chain 
get phosphorylated by the myosin kinase and it causes 
attachment-detachment cycling of the myosin head with actin 
filament leading to muscle contraction. 
An increase in the calcium ion concentration is the initiating agent for 
smooth muscle contraction. This increase in concentration can be caused by 
different reasons: nerve stimulation, hormonal stimulation, change in 
chemical environment and stretching of muscle fiber. The diversity for this 
initiation is mainly due to the presence of multiple types of receptors on the 
surface of the smooth muscle cell membrane. 
This contractile process starts reversing when the calcium ion 
concentration falls below a critical level. But the myosin head still remains in 
the phosphorylated form. Reversal of the myosin head to its normal form 
requires a myosin phosphatase that leads to stoppage of the cycling and 
cessation of contraction. 
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Inhibition of contraction also occurs when there is closure of sodium 
or calcium ions into the cells, or opening of normally closed potassium 
channels that leads to more positivity outside the cell leading to 
hyperpolarization that strongly inhibits muscle contraction. Other receptor 
mechanisms that causes inhibition of contraction are activation of the enzyme 
adenylate cyclase or guanylate cyclase. This enzyme leads to formation of 
cyclic adenosine monophosphate (cAMP) or cyclic guanosine 
monophosphate (cGMP), known as second messengers. The cAMP or cGMP 
leads to change in the degree of phosphorylation of several enzymes that 
indirectly inhibit contraction. 
 
Regulatory mechanisms 
The regulation of the contractility of smooth muscles is mainly by two 
enzymes: calcium-calmodulin-dependent protein kinase II (contributed by 
Rac/CDC/42-associated kinase) and Myosin light chain phosphatase. The 
former reduces the affinity of calcium-calmodulin complex to myosin light 
chain kinase while the latter removes the phosphate from phosphorylated 
myosin. Myosin light chain phosphatase is regulated positively by cGMP and 
negatively by G-protein rho-A-rho-associated kinase and protein kinase C 
(PKC) (30). 
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Electrical properties of the myometrium 
The cyclical depolarization and repolarization causes the sequence of 
contraction and relaxation of the uterus. Intermittent bursts of spike-like 
action potential contribute to the pacemaker activity of the myometrium (31). 
It is unclear whether there are specialized cells present to cause this 
spontaneous activity like that of the gut or in the urethra (32). A contraction 
can be initiated by a single spike, but a strong, sustained contraction requires 
a train of coordinated spikes. The action potential depends on the membrane 
ionic permeability which is both voltage-dependent and time-dependent. The 
frequency of the contraction depends on the frequency of action potentials 
within a burst, amplitude of the duration of the burst, and the duration of the 
number of simultaneously active cells (31). 
Role of sarcoplasmic reticulum 
Myometrial cells have sarcoplasmic reticulum both towards the center 
and the periphery of the cell and these possibly have different roles. SERCA 
2 a calcium-ATPase helps sarcoplasmic reticulum store calcium against a 
concentration gradient. Ca2+ can be released from the sarcoplasmic 
reticulum by two mechanisms. One is by Ca2+ itself (CICR-Ca2+ induced 
Ca2+ release) and the other is mediated by inosine triphosphate (IP3)(IICR-
IP3 induced Ca2+ Release). Both IP3 and the ryanodine receptor(RyR) are 
distributed evenly over the reticular membrane and probably use second 
messengers to release Ca2+ (33). RyR are calcium-release channels on which 
calcium acts to increase its release from the sarcoplasmic reticulum. IP3 is 
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present in minimal quantities in the cell and can be increased in quantity with 
the help of certain agonists through hydrolysis of phosphatidyl inositol 4,5 
bisphosphate (PIP2). There are three isoforms each of IP3 and RyR present in 
the myometrium. All three forms of both the receptors are present in the 
human myometrium. The predominant RyR form is RyR3 and its expression 
seems to be down-regulated towards the end of gestation. All three isoforms 
of IP3 receptors have been found to be present in human myometrium and 
their expression does not change throughout pregnancy. 
Intracellular levels of calcium have to be reduced for relaxation of the 
myometrial cell. Calcium is extruded out of the cell by plasma membrane 
Ca2+ ATPase (PMCA) and a Na-Ca exchanger (NCX). These mechanisms 
are more important than SERCA 2-dependent Ca2+ intake into the 
sarcoplasmic reticulum. Level of PMCA has been shown to increase with 
progressing pregnancy. Blocking of CICR by ryanodine has been shown not 
to reduce the spontaneous contraction or contractility of the cell in rats. 
Oxytocin causes contraction of cells by multiple mechanisms: decreasing 
Ca2+ efflux, increasing Ca2+ influx and through IICR. Much about the role 
of sarcoplasmic reticulum in uterine contractility is under study and not 
clearly understood at present. 
Contractant Pathways 
The major receptors involved in contraction of the myometrial cell are 
tyrosine kinase receptor (TKR) and G-Protein coupled receptors (GPCR). 
Both these receptors activate phospholipase C (PLC). Oxytocin and 
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prostaglandins act via GPCRs. PLCβ1-4 subfamily gets activated by Gαq/II 
subfamily, while PLCβ2 and PLCβ3 gets activated by Gβγ released from the  
Gαi complex and PLCδ gets activated by Gαh. PLC helps in the production 
of diacylglycerol (DAG) and IP3. IP3 causes release of Ca2+ from 
sarcoplasmic reticulum, which is important in sustained contractility. MAPK 
(mitogen-activated protein kinase also called ERK - extracellular-signal-
regulated kinase) pathway also can be activated by Gβγ activation. This is 
related to hormones related to contraction through GPCR and regulation of 
thin filaments. GPCR also can activate the phospholipase D pathway. 
Oxytocin 
Oxytocin GPCRs (OXTRs) predominantly act through the Gαq 
subfamily, although it can act through the Gαi and Gαh to stimulate PLCδ. 
The DAG and IP3 thus formed can stimulate contraction. Oxytocin can 
activate ryanodine receptors through TNFα-enhanced cyclic ADP-ribose 
(cADPR) pathway. Oxytocin acts through downstream pathways too. It can 
act through ERK1/2 phosphorylation suggesting involvement of the GαiGβγ- 
mediated pathway. There are multiple minor pathways by which ERK is 
activated. ERK activation plays multiple roles: contraction of the smooth 
muscle cell, stimulation of COX-2 enzyme and stimulation of PGF synthase. 
Oxytocin also induces increase in total protein synthesis and stimulates 
dephosphorylation of eukaryotic elongation factor 2 in the myometrium. 
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Prostaglandin F2α 
PGF2α acts on the prostaglandin F receptor (FP) and the thromboxane 
receptor (TP). These receptors are present in both the nucleus and the plasma 
membrane. The action of PGF2α depends on the concentration of 
extracellular calcium as it acts through the influx and efflux mechanisms on 
the cell membrane. 
Epidermal Growth Factor 
EGF acts on the epidermal growth factor receptor which stimulates a tyrosine 
kinase pathway and stimulate PLCγ activity and thereby increases IP3 
resulting in intracellular calcium release. It also has the conventional Ras 
pathway activating ERK. Its action has been associated with oxytocin 
receptor signaling too. 
Relaxant Pathways 
Relaxation of smooth muscles usually involve cyclic guanosine 
monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP). 
GPCR activate adenylate cyclase to convert ATP to cAMP, while nitric oxide 
activates guanylate cyclase to convert GTP to cGMP. They activate their 
respective protein kinases that phosphorylate proteins regulating Ca2+ 
homeostasis. The relaxant effect of β-blockers and prostaglandin E on 
myometrium is through their cAMP action (34). cAMP and cGMP 
concentrations are both regulated positively by respective cyclases and 
negatively by their phosphodiesterase, which degrades them. 
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Cyclic adenosine monophosphate (cAMP) 
cAMP, a cyclic nucleotide is a second messenger involved in a 
variety of biological processes like secretory activity, learning, modulation of 
conductance of ion channels, production of various transmitters and 
messengers. In the myometrium it causes relaxation by activation of cAMP-
dependent protein kinase (PKA) which in turn phosphorylates MLCK 
decreasing its affinity for the calcium calmodulin complex. It is formed from 
ATP by the action of the enzyme adenylate cyclase located on the inner side 
of the cell membrane. Adenylate cyclases are activated by certain GPCRs 
which have a wide range of agonists. The action of cAMP is stopped by its 
hydrolysis by certain phosphodiesterase. PDE4 (of the PDE 1—5 family 
found in myometrium) is the most abundant phosphodiesterase in the 
myometrium and its levels are significantly decreased during pregnancy 
maintaining the quiescence of uterus. Β2-adrenergic agonist also acts through 
cAMP to cause uterine relaxation. 
Cyclic guanosine monophosphate (cGMP) 
Cyclic GMP is formed by the enzyme guanylate cyclase. Guanylate 
cyclase exists in two forms: soluble and particulate. Soluble guanylate 
cyclase is completely intracellular while the membrane bound form 
(particulate) consists of a extracellular domain and two intracellular domains 
in which one domain resembles the soluble guanylate cyclase. Nitric oxide 
activates soluble guanylate cyclase to produce cGMP which activates protein 
kinase G (PKG) which phosphorylates multiple targets. It also activates 
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myosin phosphatase decreasing the rate of myosin phosphorylation. There is 
crosstalk between the cGMP pathway and the cAMP pathway. Cyclic GMP 
binds to PDE2 and increases the hydrolysis of cAMP (35). 
 
Ion channels involved in contraction 
 
L-type voltage-dependent Ca2+ channels 
These channels have a major role in sustaining contraction. The alpha 
subunit consists of the channel pore and drug binding sites along with the 
voltage sensor while the rest of the channel (alpha2, delta, gamma) subunits 
modulate the activity of the channel (36). The concentration of this channel 
varies with different layers of muscle and also with duration of gestation (37). 
Blockers of this channel reduce both spontaneous and induced contractions 
(38). Gβγ, PI-3K and PKC of the GPCR pathway can stimulate L-type 
channels. Oxytocin opens Ca2+-activated chloride channels, which indirectly 
stimulate these channels (39). 
T-type Ca2+ channels 
These are usually associated with spontaneous contractile activity in smooth 
muscles. They are also involved in calcium oscillations (Ca2+ oscillations are 
transient elevations of intracellular calcium followed by rapid decay, so that 
it can act as an intracellular signal. Also it helps in the survival of the cell 
since prolonged elevated calcium concentrations can be lethal to the cell). T-
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type Ca2+ channels have been found to be present in human myometrium too 
(40). Inhibition of spontaneous contraction and oxytocin induced myometrial 
contractions by T-type Ca2+ channel blockers have been shown in the 
caprine (goat) myometrium previously (41). 
 
Transient receptor potential channels 
These channels can cause an entry of a non-selective cation or 
calcium when activated. They can respond to hypoxia and stretch along with 
hormonal signals in smooth muscle cells (42). They are reported to modulate 
cell migration, differentiation and growth, depolarization and tone of the 
smooth muscle. The transient receptor potential channel consists of multiple 
subfamilies: TRPM, TRPC, TRPV, TRPA, TRPP, TRPML, and TRPN. 
These channels establish the importance of other cations involved in the 
contraction of human myometrium. 
 
Potassium channels 
There are multiple potassium channels involved in the contractility of 
the uterus. These include the ATP-sensitive, voltage-activated and calcium 
activated potassium channels along with other newer channels. Potassium 
ions are involved mainly in reducing the excitability of the myometrium by 
an outward K+ current causing hyperpolarization or repolarization. The 
potassium channel is made of a six-transmembrane domain molecule. The six 
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domains S1—S6 form a pore-forming hairpin loop. Four such units join 
together to form the channel. Membrane voltage is detected by the S-4 
domain. There is a unique signature of eight amino acids (TXXTXGYG) 
present within the pore of all the potassium channels identified till date 
(43,44). 
  
Calcium‑sensitive potassium (BKCa) 
These are a collection of three different channels namely the small 
conductance potassium channels, intermediate conductance potassium 
channels and the large conductance potassium channels (denoted BKCa, 
Maxi K). In this the BKCa is widely distributed throughout the body and has 
widely been studied in the human myometrium. BKCa is also the 
predominant channel present in the human myometrium both in the pregnant 
and the non-pregnant state. It is found that in different stages of pregnancy 
and towards labor the function and expression of these channels are different. 
When these channels are sensitive to calcium it is termed as BKCa channel 
but when they don’t have any calcium or voltage sensitivity they are termed 
as BK-channel (45). 
These classes of channels are both voltage-dependent and calcium-
dependent with a conductance of around 150–200 pS (46). These channels 
are blocked by tetraethylammonium, 4-aminopyridine and more selectively 
by iberiotoxin. The structure of the channel resembles that of the voltage 
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gated potassium channels except for the addition of the S7 – S10 domains. 
S1-S6 region have been attributed to the voltage dependence and the carboxy 
terminus to the calcium dependence. The BKCa channel has a α and a β 
subunit and their heterologous expression together is thought to increase the 
sensitivity for calcium (47). The quiescence of the human myometrium 
during pregnancy is maintained by the BKCa channel by its opposing 
potassium currents. During labor BKCa loses sensitivity to both voltage 
stimulation and increased intracellular calcium which helps in parturition 
(45). 
 
Voltage-gated potassium channels 
There is very little known about this channel and its significance in 
the human myometrium. There are multiple types- rapidly acting, slow acting 
and the transiently acting potassium channels present in the human 
myometrium. There are more types of potassium currents in the pregnant 
myometrium (48) which necessitates further study on these channels. In a 
mouse model it has been shown that voltage-gated potassium (Kv) channels 
have regulatory role in uterine contractility (49). In vascular smooth muscle 
the  role of Kv channels has also been proven (50). 
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ATP-sensitive potassium channels 
These channels are unique in that they respond to metabolic activities 
of the cell. They close in response to increased intracellular ATP levels. They 
are a subtype of inward rectifier potassium channels. Their role in smooth 
muscles is unclear although their roles in vascular, cerebral and visceral 
organs are well studied. The classical example of their function is in pancreas 
where they cause insulin release. They have got two subunits: the pore 
forming channel and the sulphonylurea receptor. ATP acts on the pore 
forming channel subunit while the antidiabetic drug sulfonylureas act on the 
sulphonylurea receptor subunit. There is some electrophysiological evidence 
of their presence in the myometrium(51) but their role in contraction in view 
of their metabolic functions is yet to be studies. 
 
Sodium and chloride channels 
Both these channels have been studied in rat myocytes (52). Sodium 
channels cause a fast inward current depolarizing the cell membrane. Nav2.1 
and Nav 2.3 are present in human myometrium and their density increases 
with pregnancy. Calcium dependent chloride channels are activated by 
increase in intracellular calcium. It results in an outward current depolarizing 
the myometrium. They may have a role in the spontaneous contraction of the 
uterus. 
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Pharmacology of drugs used in the study 
 
Potassium Chloride 
KCl is considered an universal agonist in contracting smooth muscle 
cells (53). It has been used as the agonist drug on myometrium in the 
past(54). The dose to be used has been standardized in our department 
previously (55). KCl depolarizes the cell membrane by offsetting the K+ 
equilibrium potential above the resting level. It is a classical case of an 
electromechanical coupling rather than a pharmacomechanical coupling. 
Unlike pharmacomechanical coupling, K+ will not contract a tissue in a 
calcium free solution (56). Since the final mechanism of action in both kinds 
of coupling is through opening of membrane calcium channels with an 
increase in intracellular calcium, they produce similar kind of dose-related 
increase in contractile activity. However the mechanism of KCl is not purely 
voltage-dependent and is partly due to Ca2+ sensitization. With membrane 
depolarization there is an increase in intracellular calcium, which activates 
Ca2+ -calmodulin dependent protein kinase II (CaMKII) which causes 
phosphorylation of MLC kinase resulting in a reduction in kinase activity for 
the Ca2+ -calmodulin complex (57). KCl has been found to activate ROK 
(Rho-associated protein kinase) too. Although the mechanism is unclear, it 
proves KCl’s role in calcium sensitization. 
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Tadalafil 
Tadalafil is a potent, reversible, competitive inhibitor of 
phosphodiesterase 5 (PDE5), leading to accumulation of cyclic guanosine 
monophosphate (cGMP). This drug was investigated for the treatment of 
hypertension and angina pectoris. During the initial human testing it was 
found to have minimal effect on angina but had an interesting side effect—
marked penile erection. GlaxoSmithKline company discovered the product 
and  Eli Lilly company applied for approval of the drug for erectile 
dysfunction. It was another oral drug approved for this condition after 
sildenafil. It was called by the trade name “Cialis”. Its usage is safe and is 
shown not to be related to sudden cardiac death or myocardial infarction as 
earlier believed rather it may be protective in myocardial infarction (14). It is 
absolutely contraindicated when the patients is already on nitrate therapy 
because of chance of hypotension. Sildenafil and vardenafil are 
contraindicated within 24 hours of nitrate therapy. Compared to it tadalafil 
should not be used within 48 hours of nitrate therapy. Angiotensin receptor 
blocker (Bosentan) should be used cautiously with tadalafil and dose 
adjustment of bosentan may be required. It is relatively contraindicated in 
multitherapy for hypertension and comedication with drugs which increase 
levels of tadalafil. Potent cytochrome P-450 inhibitor drugs like 
ketoconazole, itraconazole, erythromycin, HIV protease inhibitors increase 
plasma tadalafil concentrations (58). It is also been used in the treatment of 
pulmonary artery hypertension. Tadalafil is more potent for PDE5 than PDE6 
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(700 times). PDE6 is an enzyme which is normally present in the 
photosensitive receptors of retina of human beings; Ocular side effect in 
terms of changes in the perception of color hue and brightness are less in 
tadalafil compared to sildenafil and vardenafil. The selectivity for the enzyme 
PDE3 is 10,000 times less than it is for the enzyme PDE5. PDE3 is an 
important enzyme involved in the regulation of contraction of cardiac muscle. 
This lesser sensitivity offers protection even in cardiac patients. Headache, 
flushing, rhinitis, and dyspepsia are other important frequently associated 
side effects of tadalafil. 
 
Pharmacokinetics and metabolism 
Throughout the dosing range from 2.5 mg to 20 mg, tadalafil 
exposure expressed in terms of AUC, increases proportionally.  Tadalafil is 
absorbed rapidly and it is a highly plasma protein bound drug. This drug is 
metabolized predominantly by hepatic CYP3A enzyme. This enzyme causes 
formation of catechol product which after successive methylation and 
conjugation gives rise to methylcatechol glucuronide, which is a major 
circulating metabolite. Metabolites are mainly excreted in faeces(61%) and 
urine (36%). by time of dosing. Exposure was not substantially affected by 
time of dosing. Food does not have any significant effect on bioavailability. 
36 
 
  
 
 
 
 
Figure 4. Structure of Tadalafil 
Tadalafil has a mean Cmax (378 µg l−1 for 20 mg) observed at 2 h. 
Following that there is a monoexponential fall in concentration with mean t1/2 
of 17.5 hours. No clinically significant effects of age, sex, BMI were 
identified. Following once a day administration, on day 5 steady state 
concentration was achieved. Duration of action for tadalafil is 36 hours, 
highest among the other congeners (59). 
 
Pharmacodynamics 
Tadalafil has previously been found to be useful for erectile 
dysfunction to obtain and maintain penile erection for satisfactory sexual 
intercourse in a variety of causes including diabetes (vasculogenic), spinal 
cord injury (neuroreflexogenic), and nonorganic (psychogenic) causes. There 
are other drugs like milrinone, vesnarinone, and enoximone which are 
specific for cAMP-specific PDE3 inhibitors. These increase long-term 
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mortality in patients with heart failure. The selectivity of tadalafil for PDE5 is 
very specific and it does not increase the levels of cAMP and therefore do not 
cause cardio toxic adverse effects which PDE3 inhibitors are known to cause 
in the myocardium. To add to this, PDE5, the enzyme which tadalafil 
primarily inhibits is not present in human myocardium. Tadalafil also acts on 
PDE11, although the function of this enzyme is yet to be determined. 
Tadalafil produces a transient modest reduction in systolic (8 to 10 mm Hg) 
and diastolic (5 to 6 mm Hg) blood pressures. Tadalafil does not inhibit 
platelet function directly but moderately increase the inhibitory effect of 
sodium nitroprusside on platelet aggregation due to its requirement for an 
increase in NO to cause its effects. Patients taking tadalafil have reported 
recoverable visual problems. The visual problems usually encountered are 
blue-green vision, blurred vision and a supersensitive perception for light. 
The adverse effects are mostly dose related and increases with increasing 
doses. 
 
Iberiotoxin 
Venoms being a good source for containing molecules that interacts 
with ion channels. Peptidyl toxins derived from different sources has the 
ability to block voltage-dependent ion channels like Na+, K+, Ca2(+) channels. 
Iberiotoxin belongs to such a toxin that is a specific and potent inhibitor of 
high conductance, Ca2 (+) activated potassium (K+) channel. 
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Iberiotoxin is derived from scorpion Buthus tamulus. It contains 37 
amino-acid and has similarity with charybdotoxin. Charybdotoxin is another 
scorpion derived toxin having similar activity (60). Both of them are inhibitor 
of high conductance, Ca2 (+)-activated K+ channel. Iberiotoxin has some 
allosteric mechanism over charybdotoxin and there is an overall charge 
difference between these two molecules as iberiotoxin contain four extra 
acidic amino acid residue and one less basic amino acid group (61). When 
iberiotoxin is applied to the external side of the membrane it is able to block 
the skeletal muscle Ca2 (+) activated K+ channel that is present in the neutral-
planar bilayers. As tetraethylammonium binding causes inhibition of binding 
of iberiotoxin competitively, this points towards the binding of iberiotoxin to 
the channel is probably external (62).  
Iberiotoxin having a high molecular weight of 4230.85, is soluble in 
water and to be stored in -20o C 
.  
Figure 5. Structure of Iberiotoxin  
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Iberiotoxin has been used in multiple studies to check the effect of 
large conductance calcium dependent potassium current (BKCa) in different 
smooth muscles like rabbit basilar artery smooth muscle (63), bovine aortic 
smooth muscle (64), human coronary artery (65), urinary bladder (66), 
myometrium (17), nervous system (67) etc. 
 
Dimethyl sulfoxide (DMSO) 
For a long time DMSO is being commercially used as a solvent. 
DMSO is a byproduct of wood industry. In some animal studies it has been 
shown that DMSO can cause relaxation of detrusor muscle possibly by 
altering the Ca2(+) sensitivity of the microfilaments (68). DMSO also may be 
effective in lung adenocarcinoma by acting on tumor suppressor gene (69). 
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MATERIALS AND METHODS 
 
 
 
MATERIALS AND METHODS 
 
This study was conducted in the Department of Pharmacology and 
Clinical Pharmacology, Christian Medical College, Vellore. The study was 
approved by Institutional Review Board and Ethics Committee (Annexure 1). 
 
Inclusion criteria: 
o Premenopausal patients  
o Patients undergoing operation for benign medical 
conditions like fibroids, dysfunctional uterine bleeding and 
prolapse. 
 
Exclusion criteria:  
o Patient with malignant conditions  
o Post-menopausal women 
o Patients refusing informed consent. 
 
Informed Consent: 
After fulfilling the inclusion criteria, patients, who were selected for 
the study, were given informed consent sheet (Annexure).This informed 
consent form was composed of two part, one being the information sheet for 
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the patient and the other the consent sheet. Patients own language was used in 
the informed consent form as well as for conversation with the patient. In the 
information sheet details about the study were explained. It was clearly 
mentioned to the patients that the research study will be done in-vitro and it 
may not give any direct benefit to the patient. It was explained to the patients 
that even if they are not ready to give consent for the study, their surgery or 
post-operative hospital stay and treatment will not be hampered anyway. 
They were given time to discuss with their near relatives if they were in 
confusion. Their legal right to withdraw at any point of the study at their own 
will without any consequences was also impressed upon them. All their 
doubts were clarified to their utmost satisfaction. In case of their willingness 
to participate in the study one copy of information sheet with investigators 
signature was given to the patient and one copy of consent form with patient 
and witness signature was kept for study purpose. Contact information of the 
investigators were given to the patient in the information sheet for any other 
further clarification.  
 
Collection and transport of tissue: 
Myometrium sample from freshly operated uterus was transported to 
the Pharmacology laboratory in freshly prepared pre-oxygenated 
physiological salt solution (PSS). 
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The methods followed for obtaining, transporting and preparing the 
tissue were done as suggested by Crankshaw et al (27). Gynecologists were 
informed to dissect a full thickness uterine mass measuring 2cm × 2cm from 
the lateral wall of the uterus. The sample thus obtained was immediately 
transferred to ice-cold physiological salt solution. Then the sample was 
transported in an icebox filled with icepacks to the pharmacology laboratory 
within an hour. Once it reached the laboratory the sample was transferred to 
physiological salt solution (PSS) at room temperature. The PSS used was 
modified Krebs Henseleit solution.  
 
Tissue dissection and mounting 
The obtained sample was examined for orientation of muscle fibers 
under a magnifying glass. Pathologic changes like fibroids were also looked 
for. The tissue was made devoid of the serosa and the endometrium. 
Myometrial strips measuring 3mm × 3mm × 12mm were made from 
longitudinal incision on the myometrium. Weight of the each myometrial 
strip was 210 mg +/- 10 mg. One myometrial strip was mounted in a 20 ml 
organ bath with one end tied to the bottom of the chamber and the other to 
force transducer. The organ bath was filled with PSS and aerated with 
oxygen. Oxygen was bubbled through the solution constantly at a rate of 12 
bubbles per minute. The temperature of the organ bath was maintained at 
37.5°C. A resting tension of 20 milliNewtons (mN) (~2.0g) was applied to 
the tissue. It was maintained for a period of 45 minutes with frequent 
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adjustment of length (tissue stretches with tension) with a micromanipulator 
to keep the resting tension constant at 20 mN. During this 45 minutes the PSS 
in the bath was continuously washed at intervals of 10 minutes. Tissues 
which showed spontaneous contraction during this period were considered 
viable and were subjected to further experiments. An isometric force 
transducer was used to measure the contractile responses of the myometrium. 
It was connected to a student’s physiograph to record the changes. 
 
Students Physiograph 
One end of the tissue was tied to an isometric force transducer (T-305 
Force Transducer, Ft-2287, INCO, Ambala, India) and tissue tension sensed 
by the transducer was recorded using a students physiograph (INCO). A 50 
Hz filter was used between the coupler and the amplifier to dampen the 
artifacts caused by AC power supply and the instrument was earthed. The 
sensitivity of the physiograph and the balance of the force transduction 
coupler were not adjusted after initial optimization. After the equilibration 
period of 45 minutes, the baseline was readjusted and never after during the 
course of the experiment. 
 
Drugs and Chemicals 
Double distilled, water filtered with 22 nm filter (Milli-Q Advantage 
A10 Water System Production Unit, Millipore) was used to make all 
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solutions to avoid microbial contamination. KCl (Qualigens, Fisher scientific, 
Chennai, India) was dissolved in distilled water to have a molarity of 2.5 
Mol. KCl was prepared fresh every experiment day. Tadalafil (Santa Cruz 
biotechnology, Chennai, India) in pure powder form was dissolved in DMSO 
(Qualigens, Fisher scientific, Chennai, India) to get a working stock molarity 
of 2 milli mole (mMol). Iberiotoxin (Tocris, Santa Cruz biotechnology, USA) 
in pure power form was dissolved in distilled water to get a working stock 
molarity of 4 micromolar (μMol). 
Stock solutions of tadalafil and iberiotoxin were stored in a -
200 centigrade refrigerator.  All solutions were not kept for more than a 
month and fresh solutions made after each month. All the other salts which 
were used in the making of modified Krebs-Henseleit solution were bought 
from Qualigens, Fisher scientific, Chennai, India. 
 
Solutions 
The physiological salt solution (PSS) used was modified Krebs- 
Henseleit solution. Its composition was (mMol): NaCl 115.5; KCl 4.6; 
MgSO4 1.16; NaH2PO4 1.16; CaCl2 2.5; NaHCO3 21.9; and glucose 11.1. 
The drug concentrations used in the study were KCl 55mM; tadalafil 40 μM; 
iberiotoxin 100 nano-molar (nMol) 
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To achieve the desired concentrations of drugs in 20 ml PSS 440 μL 
of KCl, 400 μL of tadalafil and 500 μL of iberiotoxin was taken from the 
respective stock solutions. 
 
Selection of dose of tadalafil 
A preliminary set of experiments were done to identify the 
concentration of tadalafil which elicits a minimum appreciable response and 
the concentration which produces maximum response by logarithmic 
increments in dose titers. 
Selection of dose of iberiotoxin 
Iberiotoxin dose was selected from previously done similar studies 
(17,64,67) as the amount of iberiotoxin was limited. The dose that was used 
throughout the experiment was 100 nMol. 
 
Experimental Proctedure 
The tissue mounted in the organ bath was allowed to equilibrate for a 
period of 45 minutes with a constant tension of 20 mN. At the end of 45 
minutes the tissues which generated less than a force of 2 g contractile force 
with 55mM KCl were discarded. In case of discarding, a new strip of the 
same tissue was tried. If the tissue was able to produce enough force, then the 
entire experiment was carried on. All the drug concentrations mentioned in 
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this write-up were the concentration attained in the 20ml organ bath when the 
drug was added to the bath. The stock solutions were made in such a way that 
not more than 0.5 ml was added to the bath to prevent any dilutional effect. 
During the entire experiment the organ bath was maintained at 37.5°C by a 
heater and stirrer. The organ bath was constantly aerated with oxygen at a 
rate of 12 bubbles per minute. Each contraction was made for a duration of 
90 seconds and after each contraction the tissue was washed by changing the 
PSS in the bath 6 times, each at 3 minute interval, to ensure complete 
relaxation of the strip. The tissue was given a period of rest of 15 minutes. 
The KCl contraction was repeated till there was a series of 3 similar looking 
consecutive contractions. Tissues which did not get similar contractions 
consecutively with KCl alone were repeated with KCl contractions for 2hrs. 
If 3 consecutive responses appear similar, then the experiment was continued, 
otherwise the tissue was discarded. Last KCl response was recorded. This 
response served as an active control for the next contraction. After a washout 
period of 15 minutes, the myometrial strip was incubated with 40 μM 
concentrations of tadalafil in the organ bath for 10 minutes and then 
subjected to the contractile effect of 55 mmol KCl, with contact time of 90 
seconds. Then the myometrial strip was washed six times with PSS to attain 
the baseline. The contraction curve was recorded on a student’s physiograph. 
Tadalafil was added from the stock solution to the organ bath directly with a 
micropipette (Biohit Proline, Sartorius Lab systems). A relaxation period of 
15 minutes was used between two different concentration curves for the 
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washout of the drug and for the drug to reach back its normal resting state at 
20  mN. The myometrial strip was incubated with tadalafil in the presence 
specific channel blocker namely iberiotoxin to understand the mode of action 
of tadalafil. These concentrations were selected because they were shown to 
cause significant reduction in contractility of the myometrial strip in terms of 
decreased area under contractile curve and maximum height of contraction. 
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Chemicals and instruments used in the experiment: 
 
Figure 6:  Biohit micropipette used in the experiment 
Figure 7: Iberiotoxin used in the experiment Figure 8: Tadalafil used in the experiment 
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Measurement of height and area under concentration curve (AUCC) 
Height and AUCC was measured in computer using Adobe Acrobat 
XI software. Statistical tests were used to analyze the tissue response before 
and after the administration of test drug, and was compared against a set of 
control specimens.  
 
Statistical Analysis of experimental data 
All physiograph tracings were scanned with a scanner at the end of 
experiment in the constant format. Scanned tracings were analyzed by the 
software- “Adobe Acrobat XI”. Two parameters were measured: area under 
contractile curve (AUCC) and maximum height of contraction which are 
indirect measures of contractile force (27). Percentage inhibition values for 
the reversal of the inhibition were calculated as: 
 
Percentage inhibition =100-( 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑉𝑉𝑎𝑎𝑎𝑎𝑉𝑉𝑎𝑎 𝑉𝑉𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑎𝑎𝑒𝑒 𝑉𝑉𝑒𝑒𝑎𝑎𝑉𝑉𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑎𝑎
𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑏𝑏𝑉𝑉𝑎𝑎𝑒𝑒𝑎𝑎𝑉𝑉 𝑉𝑉𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑎𝑎𝑒𝑒 𝑉𝑉𝑒𝑒𝑎𝑎𝑉𝑉𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑎𝑎  X 100 ) 
 
In the above equation, value is either taken as the height of the 
contractile curve or the area under the contractile curve. Statistical analysis of 
the experimental data was done using nonparametric tests. To compare the 
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effect of tadalafil on height and AUCC of KCl-induced contractions, the 
Wilcoxon matched-pair sign rank test was implemented. Percentage 
inhibition of height and AUCC of KCl-induced contraction by tadalafil in 
presence or absence of a specific channel blocker iberiotoxin was also 
compared implementing Wilcoxon matched-pair sign rank test. Statistical 
significance was considered when the p-value was less than 0.05. All 
statistical analysis and generation of data plot was done using “R: A 
Language for Statistical Computing” (version 3.1.1) and R-studio (version 
0.98.1062).  
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  Instruments used in the experiment: 
 
Figure 9: Recording of uterine contractions using students physiograph 
Figure 10: Force transducer 
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Graphical representation of the methodology (Whether DMSO as a vehicle has any relaxant effect) 
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Graphical representation of the methodology (Effect of Tadalafil and reversal of tadalafil effect by Iberiotoxin) 
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RESULTS 
 
 
RESULTS 
 
The results obtained from the study are summarized here below. The 
contraction is measured as area under the contractile curve (AUCC) and 
height of contraction in a 90 second time period. 
Demographics 
Table 1. Demographics of the study patients 
Seria
l No 
Age 
(Years) 
Diagnosis Surgery performed Anesthesia 
1 48 Adenomyosis VH  SA 
2 44 Uterine leiomyoma TAH SA 
3 36 Fibroid uterus TAH with BSO  GA 
4 42 Adenomyosis TAH with BSO  GA 
5 40 Fibroid uterus TAH SA 
6 40 Endometriosis VH SA 
7 48 Abnormal uterine 
bleeding - 
leiomyoma  
LAVH with BSO GA 
8 40 Fibroid uterus  
Endometriosis 
TAH with Left Salphingo-
oopherectomy  
GA 
9 45 Fibroid uterus TAH with BSO SA 
10 42 Submucous fibroid 
uterus 
Total Laparoscopic 
Hysterectomy 
GA 
11 42 Abnormal uterine 
bleeding - 
leiomyoma 
LAVH+BSO GA 
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Abbreviations: 
TAH: Total abdominal hysterectomy;  
BSO: Bilateral Salphingo-oopherectomy  
VH: Vaginal hysterectomy;     
LAVH: Laparoscopy-assisted vaginal hysterectomy, 
SA: Spinal anesthesia;    
GA: General anesthesia 
 
All the patients were from different part from the country, so they 
were different in ethnicity. All the patients were operated for benign 
conditions and they were premenopausal. Samples from the above mentioned 
patients were viable and there were consistent contractions with KCl.   
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Viability of tissue 
After dissecting the tissue properly with adequate care so that least or 
no injury happened with the tissue, it is mounted in the organ bath under 
specified tension. During this stabilization period and even after that 
spontaneous contraction are noted denoting  
At the end of the 45 minutes resting period, tissues are checked for 
spontaneous contraction. Tissues which showed spontaneous contraction 
(Tracing 1) proceeded to the next part of the experiment. 
 
Tracing 1. Spontaneity of myometrial contraction 
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Consistency of consecutive contractions 
Each of the arrow marks indicate the point of KCl addition into the 
organ bath. The concentration of KCl used was 55mM throughout the 
experiment. Each contraction was allowed for a period of 90 seconds and 
then the tissue was washed with PSS allowing the tissue to relax for a period 
of 15minutes. Then the same procedure is repeated. The consistency in 
contraction of the three successive contractions are visibly similar both in 
relating to AUCC and height of the contractions. The samples which could 
reproduce three consistent successive contractions were used for the rest of 
the study. The samples which couldn’t reproduce this were discarded and 
therefore not included in the study. 
 
 
Tracing 2. Consistency of consecutive contractions 
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Consistency of KCl induced contraction (AUCC) 
 
 
Figure 11. Consistency of AUCC was checked with 2 consecutive 
contractions. Each set of 2 bars represent a single sample. There was no 
intra-tissue variability seen in the AUCC of study tissues.  
0
5
10
15
20
25
30
1 2 3 4 5 6 7 8 9 10 11
AU
CC
 IN
 C
M
2
SAMPLE NUMBER
KCl 1 KCl 2
59 
 
Consistency of KCl induced contraction (Height) 
 
 
Figure 12 .Consistency of height was checked with 2 consecutive 
contractions. Each set of 2 bars represent a single sample. There was no 
intra-tissue variability seen in the height of contraction of study tissues. 
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Effect of Vehicle (DMSO) on myometrium 
 
Table 2. Effect of DMSO at 400 μL volume on KCl-induced contraction (Height and AUCC) 
 
 
Drug administration              Height in mm              AUCC in cm2 
Mean (SEM) Mean (SEM) 
55 mM KCl            33.21 ( 3.88)             6.86 (0.87) 
55 mM KCl +  
400 μL DMSO 
        31.69 (3.63)             6.59 (0.86) 
P-value 0.19                             0.53 
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Vehicle Effect 
 
 
 
Figure 13. DMSO has minimal effect on height of the contraction induced by KCl. Each pair (2 bars) represents a single 
sample before and after incubation with DMSO. 
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Vehicle Effect 
 
Figure 14. DMSO has minimal effect on AUCC of the contraction induced by KCl. Each pair (2 bars) represents a single 
sample before and after incubation with DMSO.
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Figure 15. Boxplot showing the median, interquartile range and 
range of the AUCC of DMSO’s effect on the myometrial tissue 
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Figure 16. Boxplot showing the median, interquartile range and 
range of the height of contraction of DMSO’s effect on the 
myometrial tissue  
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Effect of Tadalafil on myometrium 
 
Table 3. Data of Tadalafil effect at 40 μM concentration on KCl-induced 
contraction 
Tadalafil (40 μM) 
Height (mm) AUCC (square cm) 
Control Test Control Test 
29.72 18.29 10.86 6.44 
34.29 29.46 9.08 7.54 
36.58 34.54 12.2 10.31 
31.75 20.82 10.37 6.73 
31.98 39.3 11.29 9.48 
28 18.7 10.91 7.33 
60.96 52.82 25.6 19.99 
15.49 9.14 5.59 3.36 
26.12 25.14 11.3 9.55 
68.33 65.02 28.89 21.9 
32.26 26.92 14.07 9.59 
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Reversal of Tadalafil-induced relaxation on KCl-induced contraction 
  
Table 4. Data of Iberiotoxin (100 nM) effect on inhibitory effect of 40 μM 
Tadalafil  
 
 
Iberiotoxin 100 nM 
Height (mm) AUCC (square cm) 
Control Test Control Test 
32.89 23.07 11.55 7.79 
34.49 50.71 8.96 15.59 
31.75 30.15 11.81 10.38 
21.93 12.56 7.54 4.08 
31.98 40 8.61 12.11 
20.1 26.72 7.12 7.59 
55.62 47.9 21.7 18.07 
12.81 11.2 4.56 4.5 
18.74 23.7 7.41 8.76 
55.52 55.96 20.3 16.83 
33.81 33.12 13.83 14.67 
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Figure 17. Tadalafil 40 μM inhibits the contraction (Height) induced by KCl. Each set of 2 bars represent a 
single sample; each before and after adding tadalafil 40 μM. 
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 Figure 18. Tadalafil 40 μM inhibits the contraction (AUCC) induced by KCl. Each set of 2 bars represent a 
single sample; each before and after adding tadalafil 40 μM. 
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 Figure 19. Iberiotoxin 100 nM reverses the contraction (height) induced by KCl. Each set of 2 bars 
represent a single sample; each before and after adding tadalafil 40 μM and iberiotoxin 100 nM. 
0
10
20
30
40
50
60
1 2 3 4 5 6 7 8 9 10 11
HE
IG
HT
 IN
 M
M
SAMPLE NUMBER
Reversal of KCl induced contraction - height 
(by Iberiotoxin 40μM)
Control Test
70 
 
 Figure 20. Iberiotoxin 100 nM reverses the contraction (AUCC) induced by KCl. Each set of 2 bars 
represent a single sample; each before and after adding tadalafil 40 μM and iberiotoxin 100 nM. 
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Figure 21. Boxplot showing the median, interquartile range and range of the 
AUCC of tadalafil’s effect on the myometrial tissue 
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Figure 22. Boxplot showing the median, interquartile range and range of the 
Height of tadalafil’s effect on the myometrial tissue.  
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Figure 23. Boxplot showing the median, interquartile range and range of the 
AUCC of Iberiotoxin and tadalafil’s effect on the myometrial tissue 
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Figure 24. Boxplot showing the median, interquartile range and range of the Height 
of Iberiotoxin and tadalafil’s effect on the myometrial tissue 
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Inhibitory effect of Tadalafil on non-pregnant myometrium 
 
Table 5. Effect of 40 μM tadalafil on KCl-induced contractility of isolated non-pregnant human 
myometrium tissue (n=11 for each drug administration)  
 
 
 
 
 
Drug administration  Height in mm         AUCC in cm2 
              Mean (SEM)                    Mean (SEM) 
55 mM KCl  35.92 ( 4.61)           13.65 (2.13) 
55 mM KCl +  
40 μM tadalafil 
                          30.90 (4.92)          10.2 (1.47) 
P-value                0.018                         0.0009 
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Reversal of tadalafil effect by iberiotoxin 
 
Table 6. Effect of Iberiotoxin on 40 μM tadalafil’s inhibition of KCl-induced contractility of isolated non-
pregnant human myometrium tissue (n=11 for each drug administration) 
 
 
 
Drug administration            Height in mm AUCC in cm2 
Mean (SEM)                Mean (SEM) 
55 mM KCl             31.78 ( 4.16) 11.21 (1.65) 
55 mM KCl +  
40 μM tadalafil + 
100 nM iberiotoxin 
          32.28 (4.50) 10.94 (1.47) 
P-value 0.9                      0.7 
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Tracing 3. Effect of DMSO on 55 mM KCl-induced 
 
Tracing 4. Effect of Tadalafil (40μM) on 55 mM KCl-induced 
 
Tracing 5. Effect of 100 nM Iberiotoxin on 40μM Tadalafil induced relaxation 
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Table 7. Comparison of median and interquartile range before and after 
giving tadalafil 40 μM and iberiotoxin 100 nM 
Drugs Median Interquartile 
Range 
KCl (55 mM) Area 11.29 10.62 - 13.14 
 
Height 31.98 28.86 - 35.44 
 
KCl (55 mM) + 
Tadalafil (40 μM) 
Area 9.48 7.03 - 09.95 
 
Height 26.92 19.76 - 35.44 
 
KCl (55 mM) Area 8.96 7.48 -  12.82 
 
Height 31.98 21.02 - 34.15 
 
KCl (55 mM) + 
Tadalafil (40 μM) + 
Iberiotoxin (100 nM) 
Area 10.38 7.69 -  15.13 
 
Height 30.15 23.39 - 43.95 
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Table 8. Percentage inhibition (median value) by Tadalafil and P-value 
 
 
 
Drugs % inhibition of 
tadalafil (Median 
value) 
% inhibition of tadalafil 
and iberiotoxin 
(Median value) 
P –value between 
percentage 
inhibitions 
(before and after 
giving iberiotoxin) 
Area 
 
 
Height 
24.19 1.32 0.009 
14.08 2.04 0.01 
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DISCUSSION 
 
 
DISCUSSION 
 
Phosphodiesterase 5 inhibitors are known to relax smooth muscles 
through their action on specific phosphodiesterases increasing the levels of 
cGMP in the cell (71). This results in an increase in protein kinases which 
reduce the intracellular calcium levels. Recently the action of other PDE5 
inhibitors on the term non-labor pregnant human myometrium was studied by 
Khan et al (18). Interestingly, the current pattern studied and specific 
antagonists tested on isolated human myometrium suggested the action of 
PDE5 inhibitors (tadalafil) on calcium activated potassium channel (BKCa) 
(18). This suggestion was also strengthened by the fact that the well 
characterized phosphodiesterase 5 inhibitor zaprinast has no effect on the 
contractility of the uterine smooth muscle (72). The concentration of tadalafil 
used in that study (18) was high enough to inhibit the entire family of 
phosphodiesterases and not just the phosphodiesterase 5. This along with the 
loss of sensitivity of BKCa receptors to both voltage and intracellular 
increase in calcium levels in pregnancy (45) prevent the use of tadalafil in 
pregnancy as tocolytic in preterm labor. However the effect of tadalafil on the 
human non-pregnant myometrium has not been studied before. 
Our results have shown that tadalafil relaxes the non-pregnant human 
myometrial contraction induced by 55mM KCl. This was observed as a 
reduction in both the maximal height and area under the contractile curve. 
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Also, this relaxation with tadalafil was reversed significantly by the addition 
of 100 nM iberiotoxin. 
In similar previous studies it was found that Tetraethylammonium, a 
non-specific BKCa channel blocker, also increased the spontaneous 
contractility of myometrial tissue. The relaxant effect of PDE5 inhibitor was 
not reversed both by the specific adenylate cyclase inhibitor or specific 
guanylate cyclase inhibitor. In fact an increase in relaxant effect of PDE5 
inhibitors on KCl-induced contraction was seen when these agents were 
added. This suggests that PDE5 inhibitors acts through the calcium-activated 
potassium channel pathway rather than its phosphodiesterase action. Cyclic 
adenosine monophosphate (cAMP) is known to be major second messenger 
involved in the relaxation of human myometrium. It is hydrolyzed mainly by 
PDE4. Tadalafil and other PDE5 inhibitors are known to have a minimal 
effect on the cAMP levels in myometrium (73). Also cAMP reduces PDE5 
expression in myometrial cells (74). Though the level of effect of tadalafil on 
cAMP is low, it still can be significant because of the sheer amount of 
relaxation the cAMP-PKA pathway causes. Cyclic GMP is known to activate 
BKCa channel as evidenced by the action of cGMP elevating agents on 
smooth muscle cells previously. This may explain the additional inhibition of 
contraction as reduced cAMP levels will reduce the baseline activation of 
BKCa by cAMP. Tadalafil probably acts by a different pathway other than 
increasing cAMP levels. 
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Phosphodiesterase 5 inhibitors are inhibitors of the 
phosphodiesterases involved in the hydrolysis of cyclic guanosine 
monophosphate (cGMP). This causes an increase in the levels of cGMP, 
which activates protein kinase G and induces relaxation by decreasing 
intracellular calcium levels. A study done with various phosphodiesterase 
inhibitors on human myometrium found that relaxant action of PDE5 and 
PDE3 inhibitors were minimal and that of PDE4 inhibitors to be significant 
in combination with β2-adrenoreceptor agonists (72). Also the amount of 
PDE4 enzyme present in the cell is significantly more than all the other 
phosphodiesterase combined. As mentioned before zaprinast, the selective 
PDE5 inhibitor also doesn’t have any effect on myometrial contractility (72). 
The amount of cGMP expressed in myometrium is least in the non-pregnant 
state when compared with a term uterus or more so with a preterm uterus (71) 
although the sensitivity of myometrium to cGMP decreases throughout 
pregnancy (not only at term) (75). The importance of cGMP in uterine 
quiescence during pregnancy is yet unclear. The data available on cGMP in 
non-pregnant myometrium is little and whatever present is also in relative to 
pregnant myometrium. In one previous study it has been shown by Winston, 
et al that, oxadiazolo quinoxalin-1- (ODQ) a selective irreversible inhibitor of 
soluble guanylyl cyclase, decrease its activity. In that study it came was 
concluded that the absence of reversal of inhibition in the presence of ODQ 
showed the independence of sildenafil-induced inhibition on the cGMP 
pathway (17). Cyclic GMP stimulates PKG which may activate the BKCa , 
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lack of which may have resulted in the increased inhibition seen when given 
along with tadalafil. 
Tetraethylammonium, the quaternary ammonium cation, acts on the 
BKCa receptor only at lower concentrations (1-2mM) (76). TEA 1mM has 
been shown to block BKCa and the same effect could be reversed with 
verapamil, showing that TEA activates voltage gated calcium channels 
through its action on BKCa. It inhibits other types of potassium channels at 
higher concentrations. Studies done previously with 20mM 
tetraethylammonium have also shown to reverse PDE5 inhibitor-induced 
relaxation of the contracted myometrium (18). But that effect cannot be 
attributed to BKCa channel because of the non-specific nature of the dose. 
Voltage-gated potassium channels get reversed by 10mM TEA (77). This 
shows that the proposed action through BKCa receptors, although the major 
mechanism, is probably not the only mechanism by which tadalafil acts. 
Spontaneous contractions induced by BKCa blockers is a known 
phenomenon and was also seen in the present study (72)
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CONCLUSION 
 
 
CONCLUSION 
 
In conclusion, we can say, this study has shown that suitably low 
concentrations of tadalafil inhibit the contractility of the isolated 
non‑pregnant human myometrium. The likely mechanism that is involved is 
by opening of the BKCa channel, as suggested from the results. The results 
also suggest that tadalafil has the potential to be used in clinical conditions 
like preterm labor or dysmenorrhea, requiring inhibition of myometrial 
contractility. 
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LIMITATION OF THE STUDY 
 
The semiquantitative nature of the study can be a limitation of this 
study.  
Isolated myometrium contractility may vary with age, disease 
condition or hormonal therapy. KCl was the only agonist used, which can 
give a different result from a pharmacological agonist like oxytocin a GPCR 
agonists which will contribute to Ca2+ -sensitization also.  
The electromechanical coupling of KCl does not involve G-proteins 
which happens in pharmacomechanical coupling (78). However recent 
studies have shown KCl’s involvement in Ca2+ -sensitization (57).  
Further endometrium has a number of celltypes which secrete 
multiple substances which affect the contraction of myometrium (79). 
Removing endometrium is necessary to sort out the various actions of the test 
substance on the myometrium, at the same time also fails to give the net 
effect as it would happen normally in vivo.
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FUTURE SCOPE 
 
 
Future Scope 
Tadalafil has good uterine relaxing properties. It has been shown to be 
safe in pregnant women too. Clinical trials are required to prove its practical 
use as tocolytic in preterm labor and also as a spasmolytic in dysmenorrhea. 
More BKCa channel blockers should also be employed in such studies in 
future. 
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Informed consent format 
PARTICIPANT INFORMATION SHEET  
 
Title of the study 
Study of the effect of Tadalafil on the contractility of isolated non-
pregnant human myometrium. 
Name of participant _______________________________________ 
Hospital No._________________ Date_____/_____/________ 
 
Dear Participant, 
I. You are invited to take part in this research study. The information in 
this document is meant to help you decide whether or not to take part 
in this study. This study is being conducted in the Department of 
Pharmacology and the Department of Obstetrics and Gynecology at 
Christian Medical College, Vellore. 
II. Please read the instructions mentioned below carefully before signing 
the written informed consent document for participation in this study. 
Please feel free to ask if you have any queries or concerns. 
III. In this study we will analyze the effects of a drug named Tadalafil on 
the uterine tissue. This study evaluates the propensity of the drug to 
relax the uterine muscle. If it causes relaxation, then this drug can 
possibly be used for the treatment of preterm labor (It is delivery of 
the premature baby before normal gestational period). 
IV. We will collect a small strip of tissue from the uterus after its surgical 
removal. The tissue for the study will be taken only after adequate 
tissue has been sent for all the necessary investigations including 
biopsy, if needed.  
V. You do not have to undergo any extra procedure to obtain this strip as 
it will be taken from the operative specimen which will be removed as 
a part of your current surgery. 
VI. The effect of the drugs will be studied on the tissue and the specimen 
used will be discarded soon after each experiment. The data obtained 
will be stored without compromising your identity and confidentiality 
and the privacy of your medical information will be maintained. 
VII. By signing this document, you will be allowing the research team 
investigators, other study personnel, Institutional Ethics Committee 
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and any person or agency required by law (like the Drug Controller 
General of India) to view your data if required.  
VIII. This study may not bring you any direct benefit, however if the drug 
is shown to be effective in relaxing the uterine tissue it may become 
useful to other women suffering from preterm labor.  
IX. Your participation in this research is purely voluntary. If you decide 
not to participate in this research study, it will in no way affect your 
medical care or your relationship with the treating doctor or the 
investigator or the institution. Also you have the right to withdraw 
from this study at any time of the study without giving any reason.   
Thanking you for your co-operation 
yours sincerely, 
 
 
Dr.Sumalya Sen  
Principal Investigator 
 
Contact Persons for any queries 
1) Dr Sumalya Sen(Principal Investigator) 
Department of Pharmacology,  
Christian Medical College, Vellore. Pin: 632002 
Phone Number: 0416 2284237 
Mobile: 09566753246 
Email:  sumalyasen@cmcvellore.ac.in 
 
2) Dr.Blessed Winston (Co-Investigator) 
Department of Pharmacology,  
Christian Medical College, Vellore. Pin: 632002 
Phone No: 0416 2284237 
 
3) Dr. Jacob Peedicayil 
Department of Pharmacology 
Christian Medical College, Vellore. Pin: 632002 
Phone Number: 0416-2284237 
Fax: 0416-2284237 
Email: jpeedi@cmcvellore.ac.in 
In case of any conflicts, you can contact: 
Dr. Abraham Peedicayil 
Professor and Head, Department of Obstetrics and Gynaecology, Unit I 
CMC Vellore, Phone Number: 04162283395 
 
102 
 
INFORMED CONSENT FORM  
Title of the study  
Study of the effect of Tadalafil on the contractility of isolated non-pregnant 
human myometrium. 
 
Name of participant__________________________ Age_______ 
Hospital No._________    Date___/___/__      Study No.______ 
 
To whomsoever it may concern 
1. I confirm that I have read and understood the participant information 
sheet for the above study and have had the opportunity to clarify all my 
doubts.[ ] 
2. I have had the consent document explained to me in my native language. 
[  ] 
3. The nature of the study has been explained to me and I state that my 
participation in the study is purely voluntary. I understand that I am free 
to withdraw at any time of the study without giving any reason, without 
my medical care or legal rights being affected. [  ] 
4. I hereby give permission to the investigators, to use the data obtained 
from studying the effect of drugs on tissue obtained from the discarded 
uterus for publication and to release any information obtained from this 
study, to Government agencies, the Ethics Committee and the Regulatory 
authorities. I understand that they will not need my permission to look at 
my health records, both in respect of the current study and any further 
research that may be conducted in relation to it. I agree to this access. [  ] 
5. I understand that the data obtained can be used in further studies without 
compromising my identity. [  ] 
6. I understand that my identity will not be revealed in any information 
released to third parties or published.[  ] 
7. I agree not to restrict the use of any data or results that arise from this 
study provided such a use is only for scientific purpose(s). [  ]  
8. I have had my questions answered to my satisfaction. [  ]  
9. I agree to take part in the above study. [  ]  
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I am aware that if I have any questions pertaining to the study at any time 
during this study, I can contact any one of the addresses listed as contact 
persons in the Participant Information Sheet.  
By signing this consent form, I give my voluntary consent to participation in 
this study and I attest that I have understood all the information given in this 
document  
 
Signature (or thumb impression) of the Subject/Legally Acceptable 
Representative  
 
 
Signatory’s Name _______________________________________ 
Date _____/_____/___________        Time _____________AM/PM 
 
Signature of the Impartial Witness 
 
 
Witness’s Name___________________________________ 
Date _____/_____/___________        Time ____________AM/PM 
 
Signature of the Investigator  
 
 
Study Investigator’s Name    Dr. Sumalya Sen 
Date _____/_____/___________       Time _____________AM/PM 
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